- Home
- SHEL vs AZN Comparison
SHEL vs AZN Comparison
Compare SHEL & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SHEL | AZN |
|---|---|---|
| Founded | 1907 | 1992 |
| Country | United Kingdom | United Kingdom |
| Employees | 96000 | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 235.4B | 285.7B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SHEL | AZN |
|---|---|---|
| Price | $85.12 | $195.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 1 |
| Target Price | ★ $80.90 | N/A |
| AVG Volume (30 Days) | ★ 5.6M | 1.9M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 3.40% | 1.64% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.70 | $10.13 |
| Revenue Next Year | $6.11 | $6.21 |
| P/E Ratio | ★ $26.62 | $31.91 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $58.55 | $61.24 |
| 52 Week High | $86.78 | $212.71 |
Technical Indicators
Market Signals| Indicator | SHEL | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 66.11 | 62.31 |
| Support Level | $71.04 | $89.28 |
| Resistance Level | N/A | $211.32 |
| Average True Range (ATR) | 1.36 | 3.22 |
| MACD | 0.22 | -5.21 |
| Stochastic Oscillator | 78.04 | 25.10 |
Price Performance
Historical ComparisonAbout SHEL Shell PLC (each representing two (2))
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2024, it produced 1.5 million barrels of liquids and 7.7 billion cubic feet of natural gas per day. At year-end 2024, reserves stood at 9.6 billion barrels of oil equivalent, 48% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with a capacity of 1.6 mmb/d located in the Americas, Asia, and Europe, and sells about 12 million tons per year of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.